APLS Apellis Pharmaceuticals Inc.

26.24
-1.11  -4%
Previous Close 27.35
Open 27.53
Price To Book 7.39
Market Cap 1,659,220,170
Shares 63,232,476
Volume 302,890
Short Ratio
Av. Daily Volume 424,534

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2019.
Discovery (APL2-201)
Complement-dependent Nephropathies (CDN)
Phase 2 data released June 15, 2019
APL-2 subcutaneous
Auto-immune Hemolytic Anemia (AIHA) and Cold agglutinin disease (CAD)
Phase 1b trial ongoing.
APL-2 PHAROAH
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 enrolment to be completed 1Q 2020.
APL-2 OAKS
Geographic atrophy (GA) associated with age-related macular degeneration (AMD)
Phase 3 data due December 2019.
APL-2 subcutaneous PEGASUS
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1b update due at ASH December 2, 2018 noted normalization of mean hemoglobin to 12.2 g/dL by day 85, an increase of 4.2 g/dL from baseline.
APL-2 PADDOCK
Paroxysmal Nocturnal Hemoglobinuria